DE69636656D1 - Oligonukleotidliganden mit hoher affinität für pdgf - Google Patents
Oligonukleotidliganden mit hoher affinität für pdgfInfo
- Publication number
- DE69636656D1 DE69636656D1 DE69636656T DE69636656T DE69636656D1 DE 69636656 D1 DE69636656 D1 DE 69636656D1 DE 69636656 T DE69636656 T DE 69636656T DE 69636656 T DE69636656 T DE 69636656T DE 69636656 D1 DE69636656 D1 DE 69636656D1
- Authority
- DE
- Germany
- Prior art keywords
- pdgf
- ligands
- high affinity
- hkgf
- oligonucleotide ligands
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003446 ligand Substances 0.000 title abstract 6
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 108020004414 DNA Proteins 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 102000053602 DNA Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US458423 | 1995-06-02 | ||
US08/458,424 US5731424A (en) | 1990-06-11 | 1995-06-02 | High affinity TGFβ nucleic acid ligands and inhibitors |
US458424 | 1995-06-02 | ||
US08/458,423 US5731144A (en) | 1990-06-11 | 1995-06-02 | High affinity TGFβ nucleic acid ligands |
US08/465,594 US5846713A (en) | 1990-06-11 | 1995-06-05 | High affinity HKGF nucleic acid ligands and inhibitors |
US465594 | 1995-06-05 | ||
US08/465,591 US5837834A (en) | 1990-06-11 | 1995-06-05 | High affinity HKGF nucleic acid ligands and inhibitors |
US465591 | 1995-06-05 | ||
US08/479,725 US5674685A (en) | 1990-06-11 | 1995-06-07 | High affinity PDGF nucleic acid ligands |
US08/479,783 US5668264A (en) | 1990-06-11 | 1995-06-07 | High affinity PDGF nucleic acid ligands |
US479725 | 1995-06-07 | ||
US479783 | 1995-06-07 | ||
US08/618,693 US5723594A (en) | 1995-06-07 | 1996-03-20 | High affinity PDGF nucleic acid ligands |
US618693 | 1996-03-20 | ||
PCT/US1996/008014 WO1996038579A1 (en) | 1995-06-02 | 1996-05-30 | High-affinity oligonucleotide ligands to growth factors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69636656D1 true DE69636656D1 (de) | 2006-12-07 |
DE69636656T2 DE69636656T2 (de) | 2007-10-04 |
Family
ID=27569790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69636656T Expired - Lifetime DE69636656T2 (de) | 1995-06-02 | 1996-05-30 | Oligonukleotidliganden mit hoher affinität für pdgf |
Country Status (9)
Country | Link |
---|---|
US (3) | US6207816B1 (de) |
EP (2) | EP1741780A3 (de) |
JP (2) | JP4531132B2 (de) |
AT (1) | ATE343638T1 (de) |
AU (1) | AU732820B2 (de) |
CA (1) | CA2221318C (de) |
DE (1) | DE69636656T2 (de) |
ES (1) | ES2276405T3 (de) |
WO (1) | WO1996038579A1 (de) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346611B1 (en) * | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US6344321B1 (en) * | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
US6229002B1 (en) | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
AU2004242462B2 (en) * | 1999-07-29 | 2008-01-24 | Gilead Sciences, Inc. | Nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor C-Met and to integrins |
SG157961A1 (en) | 2001-05-25 | 2010-01-29 | Univ Duke | Modulators of pharmacological agents |
AU2003239841A1 (en) * | 2002-05-06 | 2003-11-17 | Grunenthal Gmbh | Cgrp binding nucleic acids |
GB0213745D0 (en) | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
EP1552002A4 (de) * | 2002-06-18 | 2006-02-08 | Archemix Corp | Aptamer-toxinmoleküle sowie verfahren zu deren verwendung |
US8039443B2 (en) * | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US20040253243A1 (en) * | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US20050124565A1 (en) * | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
EP1620547B1 (de) | 2003-04-21 | 2014-06-18 | Archemix LLC | Stabilisierte aptamere für blutplättchen-wachstumsfaktor und ihre verwendung als onkologietherapeutika |
US20040219663A1 (en) * | 2003-04-30 | 2004-11-04 | Page Robert D. | Biopolymer array fabrication using different drop deposition heads |
US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
KR101471732B1 (ko) * | 2003-08-27 | 2014-12-16 | 옵쏘테크 코포레이션 | 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법 |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
LT3385384T (lt) | 2004-02-12 | 2020-09-25 | Archemix Llc | Aptamero terapija, naudinga su komplementu susijusių ligų gydymui |
US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
AU2005220910A1 (en) * | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
US20080214489A1 (en) * | 2004-04-19 | 2008-09-04 | Anthony Dominic Keefe | Aptamer-mediated intracellular delivery of oligonucleotides |
US7579450B2 (en) * | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
CA2578046A1 (en) * | 2004-09-07 | 2006-03-16 | Archemix Corp. | Aptamer medicinal chemistry |
BRPI0514984A (pt) | 2004-09-07 | 2008-07-01 | Archemix Corp | aptámeros para o fator de von willebrand e sua utilização como terapêuticos para doença trombótica |
US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
EP1807107B1 (de) | 2004-11-02 | 2011-09-07 | Archemix Corp. | Stabiliserte aptamere für einen aus plättchen gewonnenen wachstumfaktor und ihre verwendung als krebstherapiemittel |
JP2008532559A (ja) | 2005-03-19 | 2008-08-21 | メディカル リサーチ カウンシル | ウイルス感染の治療及び予防又は治療及び予防の改善 |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
EP1907590B1 (de) | 2005-06-30 | 2012-09-19 | Archemix LLC | T7 rna polymerase und verfahren zur herstellung von vollständig 2'-modifizierten nukleinsäuretranskripten |
EP2368868A1 (de) | 2005-10-28 | 2011-09-28 | Praecis Pharmaceuticals Inc. | Verfahren zur Identifikation von Verbindungen von Interesse mithilfe kodierter Bibliotheken |
US7922000B2 (en) * | 2006-02-15 | 2011-04-12 | Miraial Co., Ltd. | Thin plate container with a stack of removable loading trays |
MX2008011323A (es) | 2006-03-08 | 2008-11-18 | Archemix Corp | Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares. |
WO2008134077A1 (en) * | 2007-04-30 | 2008-11-06 | Archemix Corp. | Metabolic profile directed aptamer medicinal chemistry |
US20090203766A1 (en) * | 2007-06-01 | 2009-08-13 | Archemix Corp. | vWF aptamer formulations and methods for use |
US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
US20090233295A1 (en) * | 2008-01-29 | 2009-09-17 | Elias Georges | Trim59 directed diagnostics for neoplastic disease |
US8207298B2 (en) * | 2008-05-01 | 2012-06-26 | Archemix Corp. | Methods of separating biopolymer conjugated molecules from unconjugated molecules |
EP2400985A2 (de) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors |
EP2401614A1 (de) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen |
EP2401613A2 (de) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
GB0904957D0 (en) | 2009-03-23 | 2009-05-06 | Univ Erasmus Medical Ct | Tumour gene profile |
GB0915515D0 (en) | 2009-09-04 | 2009-10-07 | Ucl Business Plc | Treatment of vasculoproliferative conditions |
US8841429B2 (en) * | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
EP2558577B1 (de) | 2010-04-16 | 2018-12-12 | Nuevolution A/S | Bifunktionelle komplexe und verfahren zur herstellung sowie verwendung derartiger komplexe |
GB201013573D0 (en) | 2010-08-12 | 2010-09-29 | Ucl Business Plc | Treatment |
GB201013785D0 (en) | 2010-08-17 | 2010-09-29 | Ucl Business Plc | Treatment |
GB201014026D0 (en) | 2010-08-20 | 2010-10-06 | Ucl Business Plc | Treatment |
WO2012038744A2 (en) | 2010-09-22 | 2012-03-29 | Genome Research Limited | Detecting mutations |
EP2702173A1 (de) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Verwendung von emt-gensignaturen bei der entdeckung von krebswirkstoffen, -diagnostika und -behandlungen |
GB201120711D0 (en) | 2011-12-01 | 2012-01-11 | Univ Erasmus Medical Ct | Method for classifying tumour cells |
EP2802659A1 (de) | 2012-01-10 | 2014-11-19 | Noxxon Pharma AG | Nucleinsäuren zur spezifischen bindung an cgrp |
JP6181088B2 (ja) | 2012-03-09 | 2017-08-16 | ユーシーエル ビジネス ピーエルシー | 癌の治療 |
CA2868096C (en) | 2012-03-28 | 2019-12-31 | Somalogic, Inc. | Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions |
GB201205739D0 (en) | 2012-03-30 | 2012-05-16 | Ucl Business Plc | Treatment of acute inflammation in the respiratory tract |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP2016531901A (ja) | 2013-07-12 | 2016-10-13 | オプソテック コーポレイションOphthotech Corporation | 眼科症状を処置するまたは予防するための方法 |
CA2920508C (en) | 2013-09-09 | 2024-01-16 | Somalogic, Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
AU2015232980B2 (en) | 2014-03-17 | 2017-05-18 | Glaxosmithkline Intellectual Property Development Limited | Aptamers for topical delivery |
US9605266B2 (en) * | 2014-07-16 | 2017-03-28 | City Of Hope | Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore |
CN107249644A (zh) | 2014-10-15 | 2017-10-13 | 希望之城 | 针对转铁蛋白受体(TfR)的RNA适体 |
AU2016356717B2 (en) | 2015-11-18 | 2022-09-29 | Sio2 Medical Products, Inc. | Pharmaceutical package for ophthalmic formulations |
MX2018006171A (es) | 2015-11-18 | 2018-12-19 | Formycon Ag | Jeringa de plastico precargada que contiene un antagonista de vegf. |
JP6882738B2 (ja) | 2015-11-18 | 2021-06-02 | フォーマイコン アーゲーFormycon Ag | Vegf阻害薬の液体製剤を含んだプレフィルド薬剤シリンジ |
EP3407868A1 (de) | 2016-01-26 | 2018-12-05 | Formycon AG | Flüssigformulierung eines vegf-antagonisten |
GB201704953D0 (en) | 2017-03-28 | 2017-05-10 | Imp Innovations Ltd | Natural killer cells |
CA3063995A1 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
WO2018217995A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
AU2018374389A1 (en) | 2017-11-30 | 2020-05-07 | Arrakis Therapeutics, Inc. | Nucleic acid-binding photoprobes and uses thereof |
GB201804515D0 (en) | 2018-03-21 | 2018-05-02 | Takayuki Takakondo | Treatment of necroptosis |
GB201804514D0 (en) | 2018-03-21 | 2018-05-02 | Ucl Business Plc | Treatment of pyroptosis |
GB202002711D0 (en) | 2020-02-26 | 2020-04-08 | Ucl Business Ltd | Treatment |
TW202216188A (zh) | 2020-06-25 | 2022-05-01 | 英商梅迪繆思有限公司 | 軸突損傷之預防 |
CA3192419A1 (en) | 2020-09-15 | 2022-03-24 | Adam Byrne | Treatment of idiopathic pulmonary fibrosis |
GB202017673D0 (en) | 2020-11-09 | 2020-12-23 | Imperial College Innovations Ltd | Treatment of pulmonary arterial hypertensive |
WO2023152499A1 (en) | 2022-02-09 | 2023-08-17 | Imperial College Innovations Limited | Treatment of telangiectasia |
WO2024047368A1 (en) | 2022-09-02 | 2024-03-07 | Imperial College Innovations Limited | Natural killer cells |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3546806C2 (de) | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
EP0494264B1 (de) * | 1989-09-29 | 1997-06-18 | La Jolla Cancer Research Foundation | Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix |
US5674685A (en) * | 1990-06-11 | 1997-10-07 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
US5846713A (en) * | 1990-06-11 | 1998-12-08 | Nexstar Pharmaceuticals, Inc. | High affinity HKGF nucleic acid ligands and inhibitors |
US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5837834A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity HKGF nucleic acid ligands and inhibitors |
US5668264A (en) * | 1990-06-11 | 1997-09-16 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
IL98569A0 (en) * | 1990-06-20 | 1992-07-15 | Bristol Myers Squibb Co | Pharmaceutical compositions containing tgf-b and antagonists thereof for modulating blood pressure |
IE920562A1 (en) | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
MX9301135A (es) * | 1992-03-06 | 1993-09-01 | Steven G Reed | Metodo para tratar infecciones por patogeno de macrofago. |
AU3943793A (en) * | 1992-04-01 | 1993-11-08 | Whittier Institute For Diabetes And Endocrinology, The | Methods of inhibiting or enhancing scar formation in the CNS |
CA2155515A1 (en) * | 1993-02-19 | 1994-09-01 | Wendy Waegell | Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta. |
DE69429617T2 (de) * | 1993-04-30 | 2002-08-22 | Biognostik Ges | Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) |
EP1793006A3 (de) * | 1993-09-08 | 2007-08-22 | Gilead Sciences, Inc. | Nukleïnesaüreliganden und Produktion Verfahren dafür |
EP1889910A3 (de) * | 1993-09-17 | 2009-09-02 | SomaLogic, Inc. | Systematische Evolution von Liganden durch exponentielle Anreicherung: Photoselektion von Nukleinsäureliganden und Lösungs-SELEX |
-
1996
- 1996-05-30 US US08/973,124 patent/US6207816B1/en not_active Expired - Lifetime
- 1996-05-30 DE DE69636656T patent/DE69636656T2/de not_active Expired - Lifetime
- 1996-05-30 CA CA2221318A patent/CA2221318C/en not_active Expired - Lifetime
- 1996-05-30 AU AU58839/96A patent/AU732820B2/en not_active Expired
- 1996-05-30 EP EP06021052A patent/EP1741780A3/de not_active Withdrawn
- 1996-05-30 JP JP53664696A patent/JP4531132B2/ja not_active Expired - Lifetime
- 1996-05-30 AT AT96920573T patent/ATE343638T1/de not_active IP Right Cessation
- 1996-05-30 WO PCT/US1996/008014 patent/WO1996038579A1/en active IP Right Grant
- 1996-05-30 ES ES96920573T patent/ES2276405T3/es not_active Expired - Lifetime
- 1996-05-30 EP EP96920573A patent/EP0828849B1/de not_active Expired - Lifetime
-
2002
- 2002-08-19 US US10/223,666 patent/US20030180744A1/en not_active Abandoned
-
2006
- 2006-05-31 US US11/444,181 patent/US20060229273A1/en not_active Abandoned
- 2006-09-14 JP JP2006249182A patent/JP2007049997A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU732820B2 (en) | 2001-05-03 |
CA2221318C (en) | 2012-01-24 |
US6207816B1 (en) | 2001-03-27 |
ES2276405T3 (es) | 2007-06-16 |
WO1996038579A1 (en) | 1996-12-05 |
EP1741780A3 (de) | 2007-03-28 |
EP0828849A4 (de) | 2005-01-19 |
CA2221318A1 (en) | 1996-12-05 |
EP1741780A2 (de) | 2007-01-10 |
JP2001500362A (ja) | 2001-01-16 |
EP0828849A1 (de) | 1998-03-18 |
JP4531132B2 (ja) | 2010-08-25 |
AU5883996A (en) | 1996-12-18 |
US20030180744A1 (en) | 2003-09-25 |
US20060229273A1 (en) | 2006-10-12 |
DE69636656T2 (de) | 2007-10-04 |
EP0828849B1 (de) | 2006-10-25 |
ATE343638T1 (de) | 2006-11-15 |
JP2007049997A (ja) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE343638T1 (de) | Oligonukleotidliganden mit hoher affinität für pdgf | |
ATE470712T1 (de) | Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems | |
ATE239090T1 (de) | Methode zum generieren von einzelsträngigen dna molekülen | |
EP1975172A3 (de) | Hochaffine TGFß-Nukleinsäureliganden und -inhibitoren | |
FI106871B (fi) | Menetelmä nukleiinihapon tietyssä asemassa olevan nukleotidiemäksen tunnistamiseksi | |
PT92640A (pt) | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules by forming a colinear triplex the synthetic oligonucleotides and methods of use | |
DE69220946D1 (de) | Verwendung von nukleinsäureanaloga in diagnostischen und analytischen verfahren | |
EP1961826A3 (de) | Verfahren zur direkten Sequenzierung von Nukleinsäuren | |
DK0868530T3 (da) | Kaskade-nucleinsyreamplificeringsreaktion | |
ATE466960T1 (de) | Verwendung von nukleinsäureliganden in der durchflusszytometrie | |
DE69133018D1 (de) | Methoden zur zielrichtung von dna | |
ATE203271T1 (de) | Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung | |
ATE286123T1 (de) | Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen | |
DE59608651D1 (de) | Verfahren zur sequenzierung durch oligomerhybridisierung | |
DE3485923D1 (de) | Dna-gen, verfahren zu seiner herstellung und dieses gen enthaltendes plasmid. | |
DE69636725D1 (de) | Verfahren zur trennung und/oder erkennung von dns-molekülen | |
ATE468396T1 (de) | Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems | |
DE59708066D1 (de) | Verfahren zur erfassung und quantifizierung von nucleinsäure-molekülen | |
MX9709596A (es) | Adn catal ??tico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |